Healthcare [ 10/13 ] | Biotechnology [ 90/160 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 27, 24 | -0.81 Increased by +31.36% | -0.77 Decreased by -5.19% |
| Nov 3, 23 | -0.73 Increased by +61.38% | -0.86 Increased by +15.12% |
| Aug 8, 23 | -1.16 Increased by +11.45% | -1.25 Increased by +7.2% |
| May 9, 23 | -1.31 Decreased by -3.15% | -1.28 Decreased by -2.34% |
| Feb 28, 23 | -1.18 Increased by +16.9% | -1.42 Increased by +16.9% |
| Nov 8, 22 | -1.89 Decreased by -65.79% | -1.67 Decreased by -13.17% |
| Aug 4, 22 | -1.31 Decreased by -55.95% | -1.43 Increased by +8.39% |
| May 5, 22 | -1.27 Decreased by -67.11% | -1.5 Increased by +15.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 38.11 M Increased by +5.16 K% | -44.77 M Increased by +59.55% | Decreased by -117.47% Increased by +99.23% |
| Jun 30, 23 | 5.19 M Increased by +N/A% | -70.99 M Decreased by -2.91% | Decreased by -1.37 K% Decreased by N/A% |
| Mar 31, 23 | 2.78 M Increased by +N/A% | -79.74 M Decreased by -20.78% | Decreased by -2.87 K% Decreased by N/A% |
| Dec 31, 22 | 2.96 M Increased by +N/A% | -75.61 M Decreased by -6.01% | Decreased by -2.55 K% Decreased by N/A% |
| Sep 30, 22 | 725 K Increased by +N/A% | -110.67 M Decreased by -94.23% | Decreased by -15.26 K% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -68.98 M Decreased by -64.22% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -66.02 M Decreased by -83.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -71.33 M Decreased by -109.48% | Decreased by N/A% Decreased by N/A% |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.